EMPAGLIFLOZIN

Clinical trials for EMPAGLIFLOZIN explained in plain language.

Never miss a new study

Get alerted when new EMPAGLIFLOZIN trials appear

Sign up with your email to follow new studies for EMPAGLIFLOZIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Diabetes drug could help stop liver damage in hepatitis b patients

Disease control Ongoing

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. T…

Matched conditions: EMPAGLIFLOZIN

Phase: PHASE4 • Sponsor: The University of Hong Kong • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

EMPAGLIFLOZIN

Get alerted when new EMPAGLIFLOZIN trials appear

Diabetes drug could help stop liver damage in hepatitis b patients